Open Access

What is the evidence for empagliflozin in HFpEF?

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)
Sponsored by Boehringer Ingelheim & Eli Lilly

Congress Presentation

About the speaker

Professor Giuseppe Rosano

St Georges Medical School, London (United Kingdom of Great Britain & Northern Ireland)
99 presentations
23 followers

3 more presentations in this session

Introduction and recap.

Speaker: Professor S. Anker (Berlin, DE)

Thumbnail

Implementing empagliflozin for HFpEF treatment in my practice.

Speaker: Professor M. Boehm (Homburg, DE)

Thumbnail

Panel discussion.

Speaker: Professor S. Anker (Berlin, DE)

Thumbnail

Access the full session

SGLT2 inhibitors in practice (part 2): how do we implement new treatments in HFpEF?

Speakers: Professor G. Rosano, Professor S. Anker, Professor M. Boehm, Professor S. Anker
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb